跳至主要内容
临床试验/NCT05035732
NCT05035732撤回不适用

A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study)

M.D. Anderson Cancer Center0 个研究点开始时间: 2021年3月25日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
主要终点
To assess the diagnostic performance of 18F- Fluciclovine pelvic PET/MRI to that of pelvic mpMRI

研究概览

简要总结

To perform both PET scans and MRIs in the same setting using a simultaneous PET/MRI scanner.

详细描述

Primary Objective:

--To compare the diagnostic performance of 18F- Fluciclovine pelvic PET/MRI to that of pelvic mpMRI and to determine whether 18F- Fluciclovine pelvic PET/MRI is more accurate than a pelvic mpMRI in detecting pelvic RRPC in men with biochemical recurrence with histopathology as reference standard.

Secondary Objective:

--To study inter-reader reliability of 18F- Fluciclovine pelvic PET/MRI and pelvic mpMRI among the readers.

Exploratory Objective:

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Male patients who are 18 years and older
  • Histologically or cytologically proven prostate carcinoma s/p definitive radiation
  • Patients suspected to have BCR based on phoenix criteria (prostate specific antigen value (PSA) of 2 ng/mL above the PSA nadir)
  • Ability to understand and willingness to sign informed consent

排除标准

  • Patients with any medical condition or circumstance that the investigator believes may compromise the data collected or lead to a failure to fulfil the study requirements.
  • Patients with contraindication to undergo MRI
  • Patients with prior allergy to MRI contrast agent.
  • Extreme Claustrophobia

结局指标

主要结局

To assess the diagnostic performance of 18F- Fluciclovine pelvic PET/MRI to that of pelvic mpMRI

时间窗: through study completion, an average of 1 year

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验